Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.

doi:10.1038/s42255-024-01066-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.

Nature metabolism - 1 Jul 2024

Lee Hyun Min, Muhammad Nefertiti, Lieu Elizabeth L, Cai Feng, Mu Jiawei, Ha Yun-Sok, Cao Guoshen, Suchors Chamey, Joves Kenneth, Chronis Constantinos, Li Kailong, Ducker Gregory S, Olszewski Kellen, Cai Ling, Allison Derek B, Bachert Sara E, Ewing William R, Wong Harvey, Seo Hyosun, Kim Isaac Y, Faubert Brandon, Kim James, Kim Jiyeon

Abstract excerpt

Non-small-cell lung cancer (NSCLC) with concurrent mutations in KRAS and the tumour suppressor LKB1 (KL NSCLC) is refractory to most therapies and has one of the worst predicted outcomes. Here we describe a KL-induced metabolic vulnerability associated with serine-glycine-one-carbon (SGOC) metabolism. Using RNA-seq and metabolomics data from human NSCLC, we uncovered that LKB1 loss enhanced SGOC metabolism via...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antioxidants

Share to Carcinoma, Non-Small-Cell Lung

Share to Glycine Hydroxymethyltransferase

Share to Kelch-Like ECH-Associated Protein 1

Share to NF-E2-Related Factor 2

Share to Oxidative Stress

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed

Identifiers

PMID: 38877143
DOI: 10.1038/s42255-024-01066-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.PMID 38877143Read ↗

SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.Semantic proximity Read ↗

Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring.Semantic proximity Read ↗

The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutationsSemantic proximity Read ↗

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approachSemantic proximity Read ↗

The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.Semantic proximity Read ↗

Genomic alterations and their correlation with metabolic-related genes in lung cancer.Semantic proximity Read ↗

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancerSemantic proximity Read ↗

Shining a light on metabolic vulnerabilities in non-small cell lung cancer.Semantic proximity Read ↗

Therapeutic strategies of metabolic reprogramming in non-small cell lung carcinoma.Semantic proximity Read ↗

Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.Semantic proximity Read ↗

Targeting <i>de novo</i> lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancerSemantic proximity Read ↗

Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.